Artículo
Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study
Autor/es | Escamilla Gómez, Virginia
García-Gutiérrez, Valentín López Corral, Lucía García Cadenas, Irene Pérez Martínez, Ariadna Márquez Malaver, Francisco J. Caballero Velázquez, Teresa Espigado Tocino, Ildefonso Pérez Simón, José Antonio |
Departamento | Universidad de Sevilla. Departamento de Medicina |
Fecha de publicación | 2020 |
Fecha de depósito | 2023-04-19 |
Publicado en |
|
Resumen | Graft-versus-host disease is the main cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation. First-line treatment is based on the use of high doses of corticosteroids. Unfortunately, ... Graft-versus-host disease is the main cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation. First-line treatment is based on the use of high doses of corticosteroids. Unfortunately, second-line treatment for both acute and chronic graft-versus-host disease, remains a challenge. Ruxolitinib has been shown as an effective and safe treatment option for these patients. Seventy-nine patients received ruxolitinib and were evaluated in this retrospective and multicenter study. Twenty-three patients received ruxolitinib for refractory acute graft-versus-host disease after a median of 3 (range 1–5) previous lines of therapy. Overall response rate was 69.5% (16/23) which was obtained after a median of 2 weeks of treatment, and 21.7% (5/23) reached complete remission. Fifty-six patients were evaluated for refractory chronic graft-versus-host disease. The median number of previous lines of therapy was 3 (range 1–10). Overall response rate was 57.1% (32/56) with 3.5% (2/56) obtaining complete remission after a median of 4 weeks. Tapering of corticosteroids was possible in both acute (17/23, 73%) and chronic graft-versus-host disease (32/56, 57.1%) groups. Overall survival was 47% (CI: 23–67%) at 6 months for patients with aGVHD (62 vs 28% in responders vs non-responders) and 81% (CI: 63–89%) at 1 year for patients with cGVHD (83 vs 76% in responders vs non-responders). Ruxolitinib in the real life setting is an effective and safe treatment option for GVHD, with an ORR of 69.5% and 57.1% for refractory acute and chronic graft-versus-host disease, respectively, in heavily pretreated patients. |
Agencias financiadoras | CIBERONC |
Identificador del proyecto | CB16/12/00480 |
Cita | Escamilla Gómez, V., García-Gutiérrez, V., López Corral, L., García Cadenas, I., Pérez Martínez, A., Márquez Malaver, F.J.,...,Pérez Simón, J.A. (2020). Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study. Bone Marrow Transplantation, 55 (3), 641-648. https://doi.org/10.1038/s41409-019-0731-x. |
Ficheros | Tamaño | Formato | Ver | Descripción |
---|---|---|---|---|
Ruxolitinib in refractory acute ... | 930.0Kb | [PDF] | Ver/ | |